Small Cell Lung Cancer (SCLC)

>

Latest News

The investigational agent showed particularly strong efficacy in an ES-SCLC subgroup with a chemotherapy-free interval of 90 or more days.
Real-World Lurbinectedin Exhibits Safety and Modest Efficacy in ES-SCLC

July 18th 2025

The investigational agent showed particularly strong efficacy in an ES-SCLC subgroup, with a chemotherapy-free interval of 90 or more days.

The confirmed objective response rate among 56 patients with extensive-stage small cell lung cancer was 87.5%, all of whom experienced partial responses.
Frontline LDRT Plus Atezolizumab Combo Shows Efficacy in ES-SCLC

July 15th 2025

Results from a phase 2 study showed a median OS of 10.2 months in all patients with small cell lung cancer who received stereotactic radiation therapy.
SRS Lessens Rate of Neurologic Death vs WBRT in SCLC and Brain Metastases

July 14th 2025

Treatment with tarlatamab demonstrated intracranial responses in a real-world cohort of patients with extensive-stage small cell lung cancer.
Tarlatamab Shows Promising Real-World Activity in Extensive-Stage SCLC

July 11th 2025

HTMC0435 plus temozolomide led to an ORR of 24.5%, with a median OS of 12.0 months, in patients with platinum-sensitive and platinum-resistant small cell lung cancer.
HTMC0435 Plus Chemotherapy Yields Responses in Relapsed ES-SCLC

July 11th 2025

Latest CME Events & Activities

26th Annual International Lung Cancer Congress®

July 25-26, 2025

Register Now!

A New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and AD...

September 6, 2025

Register Now!

20th Annual New York Lung Cancers Symposium®

November 15, 2025

Register Now!

Cases & Conversations™: Integrating Novel Approaches to Treatment in First-line ALK+ mNSCLC – Enhancing Patient Outcomes with Real World Multidisciplinary Strategies

View More

2nd Annual Hawaii Cancer Conference

January 24-25, 2026

Register Now!

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

View More

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

View More

Virtual Testing Board: Digging Deeper on Your Testing Reports to Elevate Patient Outcomes in Advanced Non–Small Cell Lung Cancer

View More

PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging Strategies

View More

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

View More

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

View More